Hyppigheden af klinisk betydende fald i hæmoglobin (> 2 g/ dl), bekræftet ved gentagne målinger, var signifikant lavere hos patienter med celecoxib i forhold til NSAID- gruppen (relativ risiko 0, 29, 95% CI 0, 17- 0, 48).
The incidence of clinically significant decreases in haemoglobin (> 2 g/ dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48.